---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-019205"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:47:26.360624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunocore Q1 KIMMTRAK net sales $106.7M (+14% YoY); net income $13M vs $5M

## Summary
- KIMMTRAK net sales $106.7M, up 14% YoY; US sales $67.4M (+19.1% YoY), Europe $34.4M.
- Net income $13.0M ($0.25 diluted EPS) vs $5.0M ($0.10) in Q1 2025.
- Five-year OS data at AACR: KIMMTRAK OS rate 16% vs 8% control in metastatic uveal melanoma (HR 0.67).
- Cash and marketable securities $845M; R&D expense $61.1M, SG&A $37.9M.
- Phase 3 TEBE-AM (cutaneous melanoma) enrollment expected to complete H1 2026; topline data H2 2026.

## SEC filing metadata
- accession: 0001140361-26-019205
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/0001140361-26-019205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/ef20072537_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-019205
- JSON: https://secwatch.observer/filing/0001140361-26-019205.json
- Plain text: https://secwatch.observer/filing/0001140361-26-019205.txt

## Source-grounded claims
- claim_id: 125528fe731fbb0a0029df78f0e49f7d63cd8435
  claim: Immunocore Holdings plc reported the first quarter ended March 31, 2026 results: revenue $106.7 million, net income $13.0 million, EPS $0.25.
  evidence_excerpt: 2 ef20072537_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/0001140361-26-019205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.